Literature DB >> 28700395

Neuropsychiatric events and dolutegravir in HIV patients: a worldwide issue involving a class effect.

Farid Kheloufi1, Quentin Boucherie, Olivier Blin, Joelle Micallef.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28700395     DOI： 10.1097/QAD.0000000000001557

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  4 in total

1.  Effect of Dolutegravir and Sertraline on the Blood Brain Barrier (BBB).

Authors:  Qing Ma; Giovanni Schifitto; Charles Venuto; Andrew Ocque; Stephen Dewhurst; Gene D Morse; Ravikumar Aalinkeel; Stanley A Schwartz; Supriya D Mahajan
Journal:  J Neuroimmune Pharmacol       Date:  2020-01-15       Impact factor: 4.147

2.  Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy.

Authors:  Haidong Lu; Stephen R Cole; Daniel Westreich; Michael G Hudgens; Adaora A Adimora; Keri N Althoff; Michael J Silverberg; Kate Buchacz; Jun Li; Jessie K Edwards; Peter F Rebeiro; Viviane D Lima; Vincent C Marconi; Timothy R Sterling; Michael A Horberg; M John Gill; Mari M Kitahata; Joseph J Eron; Richard D Moore
Journal:  AIDS       Date:  2022-02-01       Impact factor: 4.632

Review 3.  Beneficial and Adverse Effects of cART Affect Neurocognitive Function in HIV-1 Infection: Balancing Viral Suppression against Neuronal Stress and Injury.

Authors:  Nina Y Yuan; Marcus Kaul
Journal:  J Neuroimmune Pharmacol       Date:  2019-08-06       Impact factor: 4.147

4.  Substance use, Unlike Dolutegravir, is Associated with Mood Symptoms in People Living with HIV.

Authors:  Lisa Van de Wijer; Wouter van der Heijden; Mike van Verseveld; Mihai Netea; Quirijn de Mast; Arnt Schellekens; André van der Ven
Journal:  AIDS Behav       Date:  2021-04-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.